Dimitrios Iliopoulos asserts that the FDA currently lacks the necessary AI expertise outside of its oncology division to create an appropriate regulatory framework for AI-driven drug development.

Athos Therapeutics utilized AI to identify novel biological targets for inflammatory bowel diseases that the speaker believes would have been undiscoverable by human scientists.

A tool with the widespread utility and accessibility of ChatGPT does not yet exist for scientists and clinicians in the drug development field.